Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Hayes AF, Montoya AK, Rockwood NJ. The analysis of mechanisms and their contingencies: PROCESS versus structural equation modeling. AMJ. 2017 Feb;25(1):76-81. doi: 10.1016/j.ausmj.2017.02.001
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life-table analysis. J Chronic Dis. 1978 Jan 1;31(8):557-60. doi: 10.1016/0021-9681(78)90043-7
Rothman KJ. A pictorial representation of confounding in epidemiologic studies. J Chronic Dis. 1975 Feb;28(2):101-8.
Rothman KJ, Keller AZ. The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. J Chronic Dis. 1972 Dec;25(12):711-6.